Reneo Pharmaceuticals Inc

Company Profile

Reneo Pharmaceuticals Inc had its IPO on 2021-04-08 under the ticker symbol RPHM.

The company operates in the Healthcare sector and Biotechnology industry. Reneo Pharmaceuticals Inc has a staff strength of 51 employees.

Stock update

Shares of Reneo Pharmaceuticals Inc opened at $6.97 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $6.72 - $7.23, and closed at $7.12.

This is a +2.01% increase from the previous day's closing price.

A total volume of 70,393 shares were traded at the close of the day’s session.

In the last one week, shares of Reneo Pharmaceuticals Inc have increased by +12.66%.

Reneo Pharmaceuticals Inc's Key Ratios

Reneo Pharmaceuticals Inc has a market cap of $213.62 million, indicating a price to book ratio of 0.4685 and a price to sales ratio of 0.

In the last 12-months Reneo Pharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-65432000. The EBITDA ratio measures Reneo Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Reneo Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -29.1% with a return of equity of -47.72%.

In Q2, Reneo Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Reneo Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-2.3 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Reneo Pharmaceuticals Inc’s profitability.

Reneo Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 1.2489. Its price to sales ratio in the trailing 12-months stood at 0.

Reneo Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$148.04 million

Total Liabilities

$13.74 million

Operating Cash Flow

$0

Capital Expenditure

$5000

Dividend Payout Ratio

0%

Reneo Pharmaceuticals Inc ended 2024 with $148.04 million in total assets and $0 in total liabilities. Its intangible assets were valued at $148.04 million while shareholder equity stood at $132.53 million.

Reneo Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $13.74 million in other current liabilities, 3000.00 in common stock, $-171321000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $9.08 million and cash and short-term investments were $142.68 million. The company’s total short-term debt was $318,000 while long-term debt stood at $0.

Reneo Pharmaceuticals Inc’s total current assets stands at $146.32 million while long-term investments were $0 and short-term investments were $133.60 million. Its net receivables were $0 compared to accounts payable of $1.83 million and inventory worth $0.

In 2024, Reneo Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $5000.

Comparatively, Reneo Pharmaceuticals Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$7.12

52-Week High

$11.295

52-Week Low

$1.79

Analyst Target Price

$25.71

Reneo Pharmaceuticals Inc stock is currently trading at $7.12 per share. It touched a 52-week high of $11.295 and a 52-week low of $11.295. Analysts tracking the stock have a 12-month average target price of $25.71.

Its 50-day moving average was $6.64 and 200-day moving average was $5.56 The short ratio stood at 12.13 indicating a short percent outstanding of 0%.

Around 204.8% of the company’s stock are held by insiders while 5891.8% are held by institutions.